An investor lawsuit alleges that Novo Nordisk misjudged the effect of rivalry from customized compounded medications when it released sales forecasts for its GLP-1 drugs, Ozempic and Wegovy, for diabetes and obesity.
The legal complaint claims that Novo issued deceptive and untrue statements to diminish the rivalry from compounders. This filing came just three days after the company appointed a new CEO, raising questions about transparency in leadership transitions.
According to court documents, Novo reduced its 2025 sales growth forecast from a 13% to 21% spread to a new bracket of 8% to 14%. The company also lowered the midpoint of its projected operating profit growth by 7%, moving from 20% down to 13%. The firm had originally released its guidance on May 7, alongside its first-quarter financial results.
The complaint was submitted to a U.S. District Court in New Jersey by investor Eric Barta. It is a class action lawsuit intended to represent shareholders who purchased Novo stock between May 7 and July 28. Barta is seeking financial recovery for alleged losses tied to the company’s misstatements.
A spokesperson for Novo acknowledged awareness of the lawsuit but rejected the accusations. They noted that, because the matter was under litigation, the company could not provide additional commentary, but it intends to contest the claims.
Last week, Novo attributed its reduced sales outlook to several challenges: ongoing use of compounded GLP-1s, slower-than-expected market expansion, and increasing competition from rival drugmakers. The firm had projected stronger growth for its semaglutide-based products, including Wegovy for weight loss and Ozempic for Type 2 diabetes.
The company’s forecast was built on the assumption that the FDA’s period of leniency—allowing compounders to sell cheaper versions of GLP-1 drugs—would end on May 22. However, Novo claimed that many compounders continued producing and marketing these drugs under the guise of customized treatments, creating pricing pressures and slowing adoption.
At the same time, Novo has faced growing competition from Eli Lilly’s tirzepatide drugs, Zepbound and Mounjaro, which have captured significant market share and are seen as strong alternatives. Investors are watching closely to see how this rivalry plays out as new data and drug launches emerge.
Last week, Novo declined to disclose updated sales figures for Wegovy and Ozempic, stating that official numbers would be released during its upcoming second-quarter earnings report. Analysts suggest that the lawsuit could add pressure on Novo to provide greater clarity and restore investor confidence.
Industry experts note that the lawsuit highlights the broader challenges pharmaceutical companies face when navigating the gray areas of compounded drug competition. For Novo, the case could become a pivotal moment in determining how aggressively it protects its semaglutide franchise while managing investor expectations.
Analysts have suggested that the lawsuit against Novo may have broader implications for the pharmaceutical industry. Investor lawsuits of this scale often highlight the tension between market expectations and the unpredictable realities of drug competition, particularly when it comes to innovative therapies such as GLP-1 medications.
Legal experts also note that if the case proceeds, it could test how courts evaluate the disclosure practices of global drugmakers. While Novo maintains that it acted appropriately, the allegations of misrepresenting the effect of compounded alternatives could raise questions about transparency in forecasting.
Market watchers emphasize that Novo has been at the center of one of the most competitive races in modern pharmaceutical history. With obesity and diabetes representing multi-billion-dollar opportunities, even slight adjustments to forecasts can shift investor confidence and stock performance.
Beyond the financial implications, the case draws attention to how regulators may approach compounded drugs in the future. The FDA has faced increasing pressure to crack down on unauthorized versions of GLP-1 medications, which could eventually benefit Novo by reducing competition. However, enforcement remains inconsistent, leaving room for legal gray areas.
